Alpha Teknova, Inc. (“Teknova” or the “Company”) (Nasdaq: TKNO), a
leading producer of critical reagents for the discovery,
development, and commercialization of novel therapies, vaccines,
and molecular diagnostics, today announced financial results for
the second quarter ended June 30, 2023.
“Today we reported strong operating results for the second
quarter of 2023, increasing revenue sequentially by 26%, despite a
challenging market environment,” said Stephen Gunstream, President
and Chief Executive Officer of Teknova. “We continue to deliver to
our growth strategy, with the recent certification of our new
state-of-the-art facility to produce GMP-grade products that will
enable us to expand our revenue capacity to $200 million. Due to
near-term headwinds persisting in bioprocessing, however, we are
reducing our 2023 revenue outlook. We nonetheless remain optimistic
about the long-term potential of our target markets.”
“During the first half of 2023, we managed our overall expenses
and capital expenditures to plan. Despite the lower revenue
outlook, we continue to expect full-year free cash outflow to
remain at approximately $30 million,” explained Matt Lowell,
Teknova’s Chief Financial Officer.
Corporate and Financial Updates
- Earned second quarter 2023 total revenue of $11.5 million, up
26% from the first quarter 2023 and slightly lower compared to the
second quarter 2022
- Received certification of our new
state-of-the-art manufacturing facility for the production of
GMP-grade products
- Expanded our proprietary product line,
AAV-Tek Solutions, by introducing an additional version of our
first-of-its-kind AEX Buffer Screening Kit for the AAV8 serotype,
as well as 24 new catalog reagents, to deliver end-to-end solutions
for gene therapy process development
- Teknova and Sartorius BIA Separations
demonstrated a reliable and scalable approach for the enhancement
of AAV full capsid enrichment with an optimized AEX Platform
- Ended the second quarter 2023 with a
cash position of $23.7 million and gross debt of $22.1 million
- Certain fixed assets were impaired,
resulting in a non-recurring, non-cash impairment charge of $2.2
million in the second quarter 2023
Revenue for the Second Quarter and
Year-to-Date
|
|
For the Three Months Ended June 30, |
|
|
For the Six Months Ended June 30, |
|
(Dollars in
thousands) |
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Lab Essentials |
|
$ |
7,581 |
|
|
$ |
8,393 |
|
|
$ |
14,838 |
|
|
$ |
15,368 |
|
Clinical
Solutions |
|
|
3,653 |
|
|
|
2,943 |
|
|
|
5,262 |
|
|
|
6,755 |
|
Other |
|
|
293 |
|
|
|
354 |
|
|
|
548 |
|
|
|
714 |
|
Total
revenue |
|
$ |
11,527 |
|
|
$ |
11,690 |
|
|
$ |
20,648 |
|
|
$ |
22,837 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Second Quarter 2023 Financial Results
Total revenue for the second quarter 2023 was $11.5 million,
down 1% compared to $11.7 million in the second quarter 2022. Lab
Essentials revenue was $7.6 million in the second quarter 2023,
down 10% compared to $8.4 million in the second quarter 2022.
Clinical Solutions revenue was $3.7 million, up 24% compared to
$2.9 million in the second quarter 2022.
Gross profit for the second quarter 2023 was $5.1 million,
compared to $5.2 million in the second quarter 2022. Gross margin
for the second quarter 2023 was 43.9%, compared to 44.9% in the
second quarter 2022. Despite increased overhead costs in the second
quarter 2023, including depreciation from our new manufacturing
facility, our gross margins were down only slightly compared to the
second quarter 2022 as higher margin Clinical Solutions revenue
represented a larger percentage of our total revenue in the second
quarter 2023 compared to the second quarter 2022.
Operating expenses for the second quarter 2023 were $12.1
million, compared to $11.9 million in the second quarter 2022.
Excluding the non-recurring, non-cash impairment charge related to
certain fixed assets of $2.2 million, operating expenses were down
$2.0 million in the second quarter 2023 compared to the second
quarter 2022. The decrease was driven by reduced spending,
primarily in professional fees and occupancy costs.
Net loss for the second quarter 2023 was $7.2 million, or
negative $0.25 per diluted share, compared to $6.2 million, or
negative $0.22 per diluted share, for the second quarter 2022.
Adjusted EBITDA for the second quarter 2023 was negative $2.3
million, compared to negative $4.9 million for the second quarter
2022. Free Cash Flow was negative $6.2 million for the second
quarter 2023, compared to negative $16.8 million for the second
quarter 2022.
2023 Outlook
Teknova is revising its fiscal 2023 outlook for revenue but
maintaining its expectation for free cash outflow. The Company now
anticipates total revenue of $37 million to $40 million for the
fiscal year ending December 31, 2023 (“2023”), which assumes a Lab
Essentials range from down 9% to down 5% and a Clinical Solutions
range from down 15% to up 5%. The Company continues to anticipate a
free cash outflow amount of approximately $30 million for 2023.
Upcoming Investor Conference
Sidoti Virtual Micro-Cap ConferenceThursday, August 17, 2023 at
2:30 p.m.
EThttps://sidoti.zoom.us/webinar/register/WN_EfIdZfmdT-6eLFcmczHxKw
Conference Call and Webcast
Teknova will host a webcast and conference call on Thursday,
August 10, 2023, beginning at 5:30 p.m. ET. Participants can access
the live webcast on the Investor Relations section of the Teknova
website and at this link:
https://edge.media-server.com/mmc/p/uwatr9e7. To receive a PIN for
dialing in, participants can register for the webcast via this
link:
https://register.vevent.com/register/BIb15ae1239db14699b0b6f88ed3ff392a.
The webcast will be available for replay on the Company’s website
approximately two hours after the event.
About Teknova
Teknova makes solutions possible. Since 1996, Teknova has been
innovating the manufacture of critical reagents for the life
sciences industry to accelerate the discovery and development of
novel therapies that will help people live longer, healthier lives.
We offer fully customizable solutions for every stage of the
workflow, supporting industry leaders in cell and gene therapy,
molecular diagnostics, and synthetic biology. Our fast turnaround
of high-quality agar plates, microbial culture media, buffers,
reagents, and water helps our customers scale seamlessly from RUO
to GMP. Headquartered in Hollister, California, with over 200,000
square feet of state-of-the-art facilities, Teknova’s modular
manufacturing platform was designed by our team of scientists,
engineers, and quality control experts to efficiently produce the
foundational ingredients for the discovery and commercialization of
novel therapies.
Non-GAAP Financial Measures
This press release contains financial measures that have not
been calculated in accordance with U.S. generally accepted
accounting principles (GAAP). Teknova uses the following non-GAAP
financial measures in assessing the performance of its business and
the effectiveness of its business strategies: (a) Adjusted EBITDA
and (b) Free Cash Flow.
Teknova defines Adjusted EBITDA as net loss adjusted for
interest income (expense), net, benefit from income taxes,
depreciation expense, amortization of intangible assets, and
stock-based compensation expense. Adjusted EBITDA reflects further
adjustments to eliminate the impact of certain items, including
certain non-cash and other items that Teknova does not consider
representative of its ongoing operating performance.
Teknova defines Free Cash Flow as cash used in operating
activities less purchases of property, plant, and equipment.
Teknova presents Adjusted EBITDA and Free Cash Flow in this
press release because Teknova believes that analysts, investors,
and other interested parties frequently use these measures to
evaluate companies in Teknova’s industry and that such measures
facilitate comparisons on a consistent basis across reporting
periods. Teknova also believes such measures are helpful in
highlighting trends in Teknova’s operating results because they
exclude items that are not indicative of Teknova’s core operating
performance. Investors should consider non-GAAP financial measures
in addition to, and not as a substitute for, or as superior to,
measures of financial performance prepared in accordance with GAAP.
The non-GAAP financial measures presented by Teknova may be
different from the non-GAAP financial measures used by other
companies.
A full reconciliation of these non-GAAP measures to the most
comparable GAAP measures is included at the end of this
release.
Forward-Looking Statements
Statements in this press release about future expectations,
plans and prospects, as well as any other statements regarding
matters that are not historical facts, may constitute
“forward-looking statements.” These statements include, but are not
limited to, statements relating to Teknova’s anticipated total
revenue, including our expectations for 2023 revenue guidance,
expected growth in Lab Essentials and Clinical Solutions, ongoing
capacity expansion, new research and development products,
prospects, including to achieve profitability, strategy of managing
operating expenses, and long-term growth strategy. The words,
without limitation, “anticipate,” “believe,” “continue,” “could,”
“estimate,” “expect,” “intend,” “may,” “plan,” “potential,”
“predict,” “project,” “should,” “target,” “will,” “would” and
similar expressions are intended to identify forward-looking
statements, although not all forward-looking statements contain
these or similar identifying words. These forward-looking
statements are based on management’s current expectations and
beliefs and are subject to uncertainties and factors, all of which
are difficult to predict and many of which are beyond Teknova’s
control and could cause actual results to differ materially and
adversely from those described in the forward-looking statements.
These risks and uncertainties include, but are not limited to,
demand for Teknova’s products (including the potential delay or
pausing of customer orders); Teknova’s assessment of fundamental
indicators of future demand across its target customer base;
Teknova’s ability to expand its production, commercial, and
research and development capabilities; Teknova’s cash flows and
revenue growth rate; Teknova’s supply chain, sourcing,
manufacturing and warehousing; inventory management; risks related
to global economic and marketplace uncertainties, including those
related to the impact of the COVID-19 pandemic; reliance on a
limited number of customers for a high percentage of Teknova’s
revenue; potential acquisitions and integration of other companies;
and other factors discussed in the “Risk Factors” section of
Teknova’s most recent periodic reports filed with the Securities
and Exchange Commission (“SEC”), including in Teknova’s Annual
Report on Form 10-K for the year ended December 31, 2022, and
subsequent Quarterly Reports on Form 10-Q filed with the SEC, all
of which you may obtain for free on the SEC’s website at
www.sec.gov. Although Teknova believes that the expectations
reflected in its forward-looking statements are reasonable, Teknova
does not know whether its expectations will prove correct. You are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date hereof, even if
subsequently made available by Teknova on its website or otherwise.
Teknova does not undertake any obligation to update, amend or
clarify these forward-looking statements, whether as a result of
new information, future events or otherwise, except as may be
required under applicable securities laws.
ALPHA TEKNOVA,
INC.Condensed Statements of
Operations(Unaudited)(In
thousands, except share and per share data)
|
|
For the Three Months Ended June 30, |
|
|
For the Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Revenue |
|
$ |
11,527 |
|
|
$ |
11,690 |
|
|
$ |
20,648 |
|
|
$ |
22,837 |
|
Cost of
sales |
|
|
6,461 |
|
|
|
6,443 |
|
|
|
13,159 |
|
|
|
12,241 |
|
Gross
profit |
|
|
5,066 |
|
|
|
5,247 |
|
|
|
7,489 |
|
|
|
10,596 |
|
Operating expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Research and development |
|
|
1,464 |
|
|
|
1,929 |
|
|
|
2,859 |
|
|
|
3,942 |
|
Sales and marketing |
|
|
2,174 |
|
|
|
2,598 |
|
|
|
4,517 |
|
|
|
4,195 |
|
General and administrative |
|
|
5,943 |
|
|
|
7,059 |
|
|
|
13,288 |
|
|
|
14,354 |
|
Amortization of intangible assets |
|
|
287 |
|
|
|
287 |
|
|
|
573 |
|
|
|
574 |
|
Long-lived assets impairment |
|
|
2,195 |
|
|
|
— |
|
|
|
2,195 |
|
|
|
— |
|
Total operating expenses |
|
|
12,063 |
|
|
|
11,873 |
|
|
|
23,432 |
|
|
|
23,065 |
|
Loss
from operations |
|
|
(6,997 |
) |
|
|
(6,626 |
) |
|
|
(15,943 |
) |
|
|
(12,469 |
) |
Other
(expenses) income, net |
|
|
|
|
|
|
|
|
|
|
|
|
Interest (expense) income, net |
|
|
(308 |
) |
|
|
28 |
|
|
|
(215 |
) |
|
|
15 |
|
Other income, net |
|
|
166 |
|
|
|
— |
|
|
|
184 |
|
|
|
— |
|
Total other (expenses) income, net |
|
|
(142 |
) |
|
|
28 |
|
|
|
(31 |
) |
|
|
15 |
|
Loss
before income taxes |
|
|
(7,139 |
) |
|
|
(6,598 |
) |
|
|
(15,974 |
) |
|
|
(12,454 |
) |
Provision for (benefit from) income taxes |
|
|
15 |
|
|
|
(395 |
) |
|
|
(3 |
) |
|
|
(754 |
) |
Net
loss |
|
$ |
(7,154 |
) |
|
$ |
(6,203 |
) |
|
$ |
(15,971 |
) |
|
$ |
(11,700 |
) |
Net loss
per share—basic and diluted |
|
$ |
(0.25 |
) |
|
$ |
(0.22 |
) |
|
$ |
(0.57 |
) |
|
$ |
(0.42 |
) |
Weighted
average shares used in computing net loss per share—basic and
diluted |
|
|
28,272,306 |
|
|
|
28,057,801 |
|
|
|
28,227,132 |
|
|
|
28,044,460 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ALPHA TEKNOVA,
INC.Condensed Balance
Sheets(Unaudited)(In
thousands)
|
|
As of June 30, |
|
|
As of December 31, |
|
|
|
2023 |
|
|
2022 |
|
ASSETS |
|
|
|
|
|
|
Current
assets: |
|
|
|
|
|
|
Cash and cash equivalents |
|
$ |
23,710 |
|
|
$ |
42,236 |
|
Accounts receivable, net |
|
|
4,572 |
|
|
|
4,261 |
|
Contract assets |
|
|
1,050 |
|
|
|
— |
|
Inventories, net |
|
|
12,018 |
|
|
|
12,247 |
|
Income taxes receivable |
|
|
22 |
|
|
|
22 |
|
Prepaid expenses and other current assets |
|
|
1,741 |
|
|
|
2,374 |
|
Total current assets |
|
|
43,113 |
|
|
|
61,140 |
|
Property, plant, and equipment, net |
|
|
52,861 |
|
|
|
51,577 |
|
Operating right-of-use lease assets |
|
|
17,561 |
|
|
|
19,736 |
|
Intangible assets, net |
|
|
16,983 |
|
|
|
17,556 |
|
Other
non-current assets |
|
|
2,030 |
|
|
|
2,252 |
|
Total assets |
|
$ |
132,548 |
|
|
$ |
152,261 |
|
LIABILITIES AND STOCKHOLDERS’ EQUITY |
|
|
|
|
|
|
Current
liabilities: |
|
|
|
|
|
|
Accounts payable |
|
$ |
1,081 |
|
|
$ |
2,449 |
|
Accrued liabilities |
|
|
3,658 |
|
|
|
6,203 |
|
Current portion of operating lease liabilities |
|
|
1,751 |
|
|
|
2,223 |
|
Current debt, net |
|
|
22,162 |
|
|
|
— |
|
Total current liabilities |
|
|
28,652 |
|
|
|
10,875 |
|
Deferred
tax liabilities |
|
|
1,219 |
|
|
|
1,223 |
|
Other
accrued liabilities |
|
|
147 |
|
|
|
191 |
|
Long-term debt, net |
|
|
— |
|
|
|
21,976 |
|
Long-term operating lease liabilities |
|
|
16,322 |
|
|
|
18,111 |
|
Total liabilities |
|
|
46,340 |
|
|
|
52,376 |
|
Stockholders’ equity: |
|
|
|
|
|
|
Preferred stock |
|
|
— |
|
|
|
— |
|
Common stock |
|
|
— |
|
|
|
— |
|
Additional paid-in capital |
|
|
157,185 |
|
|
|
154,891 |
|
Accumulated deficit |
|
|
(70,977 |
) |
|
|
(55,006 |
) |
Total stockholders’ equity |
|
|
86,208 |
|
|
|
99,885 |
|
Total liabilities and stockholders’ equity |
|
$ |
132,548 |
|
|
$ |
152,261 |
|
|
|
|
|
|
|
|
|
|
ALPHA TEKNOVA,
INC.Condensed Statements of Cash Flows
(Unaudited)(In thousands)
|
|
For the Three Months Ended June 30, |
|
|
For the Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Operating activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Net loss |
|
$ |
(7,154 |
) |
|
$ |
(6,203 |
) |
|
$ |
(15,971 |
) |
|
$ |
(11,700 |
) |
Adjustments to reconcile net loss to net cash used in operating
activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Bad debt expense |
|
|
6 |
|
|
|
25 |
|
|
|
8 |
|
|
|
32 |
|
Inventory reserve |
|
|
177 |
|
|
|
(4 |
) |
|
|
33 |
|
|
|
(8 |
) |
Depreciation and amortization |
|
|
1,297 |
|
|
|
792 |
|
|
|
2,427 |
|
|
|
1,543 |
|
Stock-based compensation |
|
|
1,070 |
|
|
|
934 |
|
|
|
2,080 |
|
|
|
1,721 |
|
Deferred taxes |
|
|
15 |
|
|
|
(391 |
) |
|
|
(4 |
) |
|
|
(751 |
) |
Amortization of debt financing costs |
|
|
120 |
|
|
|
53 |
|
|
|
210 |
|
|
|
99 |
|
Non-cash lease expense |
|
|
(16 |
) |
|
|
75 |
|
|
|
31 |
|
|
|
181 |
|
Long-lived assets impairment |
|
|
2,195 |
|
|
|
— |
|
|
|
2,195 |
|
|
|
— |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable |
|
|
199 |
|
|
|
143 |
|
|
|
(319 |
) |
|
|
(1,176 |
) |
Contract assets |
|
|
(1,050 |
) |
|
|
— |
|
|
|
(1,050 |
) |
|
|
— |
|
Inventories |
|
|
(44 |
) |
|
|
(1,479 |
) |
|
|
196 |
|
|
|
(2,507 |
) |
Income taxes receivable |
|
|
— |
|
|
|
1,071 |
|
|
|
— |
|
|
|
1,071 |
|
Prepaid expenses and other current assets |
|
|
771 |
|
|
|
190 |
|
|
|
1,042 |
|
|
|
737 |
|
Other non-current assets |
|
|
120 |
|
|
|
(373 |
) |
|
|
222 |
|
|
|
(589 |
) |
Accounts payable |
|
|
(976 |
) |
|
|
(515 |
) |
|
|
(1,362 |
) |
|
|
(278 |
) |
Accrued liabilities |
|
|
(564 |
) |
|
|
(136 |
) |
|
|
(1,234 |
) |
|
|
626 |
|
Other |
|
|
(22 |
) |
|
|
(20 |
) |
|
|
(44 |
) |
|
|
(40 |
) |
Cash used in operating activities |
|
|
(3,856 |
) |
|
|
(5,838 |
) |
|
|
(11,540 |
) |
|
|
(11,039 |
) |
Investing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Purchase
of property, plant, and equipment |
|
|
(2,338 |
) |
|
|
(10,920 |
) |
|
|
(6,650 |
) |
|
|
(16,837 |
) |
Cash used in investing activities |
|
|
(2,338 |
) |
|
|
(10,920 |
) |
|
|
(6,650 |
) |
|
|
(16,837 |
) |
Financing activities: |
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds
from long-term debt |
|
|
— |
|
|
|
5,135 |
|
|
|
— |
|
|
|
5,135 |
|
Payment
of debt issuance costs |
|
|
(24 |
) |
|
|
(151 |
) |
|
|
(24 |
) |
|
|
(151 |
) |
Payment
of exit fee costs |
|
|
— |
|
|
|
(135 |
) |
|
|
— |
|
|
|
(135 |
) |
Payment
of offering costs |
|
|
(361 |
) |
|
|
— |
|
|
|
(395 |
) |
|
|
— |
|
Proceeds
from exercise of stock options |
|
|
67 |
|
|
|
44 |
|
|
|
76 |
|
|
|
99 |
|
Proceeds
from issuance of common stock under employee stock purchase
plan |
|
|
138 |
|
|
|
144 |
|
|
|
138 |
|
|
|
144 |
|
Cash (used in) provided by financing activities |
|
|
(180 |
) |
|
|
5,037 |
|
|
|
(205 |
) |
|
|
5,092 |
|
Change
in cash, cash equivalents, and restricted cash |
|
|
(6,374 |
) |
|
|
(11,721 |
) |
|
|
(18,395 |
) |
|
|
(22,784 |
) |
Cash,
cash equivalents, and restricted cash at beginning of period |
|
|
30,215 |
|
|
|
76,455 |
|
|
|
42,236 |
|
|
|
87,518 |
|
Cash,
cash equivalents, and restricted cash at end of period |
|
$ |
23,841 |
|
|
$ |
64,734 |
|
|
$ |
23,841 |
|
|
$ |
64,734 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
ALPHA TEKNOVA,
INC.Reconciliation of Non-GAAP Measures to the
Most Comparable GAAP
Measures(Unaudited)(In
thousands)
|
|
For the Three Months Ended June 30, |
|
|
For the Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Net loss – as reported |
|
$ |
(7,154 |
) |
|
$ |
(6,203 |
) |
|
$ |
(15,971 |
) |
|
$ |
(11,700 |
) |
Add back: |
|
|
|
|
|
|
|
|
|
|
|
|
Interest (expense) income, net |
|
|
(308 |
) |
|
|
28 |
|
|
|
(215 |
) |
|
|
15 |
|
Provision for (benefit from) income taxes |
|
|
15 |
|
|
|
(395 |
) |
|
|
(3 |
) |
|
|
(754 |
) |
Depreciation expense |
|
|
1,010 |
|
|
|
505 |
|
|
|
1,854 |
|
|
|
969 |
|
Amortization of intangible assets |
|
|
287 |
|
|
|
287 |
|
|
|
573 |
|
|
|
574 |
|
EBITDA |
|
$ |
(5,534 |
) |
|
$ |
(5,834 |
) |
|
$ |
(13,332 |
) |
|
$ |
(10,926 |
) |
Other and non-recurring
expenses: |
|
|
|
|
|
|
|
|
|
|
|
|
Stock-based compensation expense |
|
|
1,070 |
|
|
|
934 |
|
|
|
2,080 |
|
|
|
1,721 |
|
Severance pay and other termination benefits |
|
|
— |
|
|
|
— |
|
|
|
725 |
|
|
|
— |
|
Long-lived assets impairment |
|
|
2,195 |
|
|
|
— |
|
|
|
2,195 |
|
|
|
— |
|
Adjusted
EBITDA |
|
$ |
(2,269 |
) |
|
$ |
(4,900 |
) |
|
$ |
(8,332 |
) |
|
$ |
(9,205 |
) |
|
|
For the Three Months Ended June 30, |
|
|
For the Six Months Ended June 30, |
|
|
|
2023 |
|
|
2022 |
|
|
2023 |
|
|
2022 |
|
Cash used in operating activities |
|
$ |
(3,856 |
) |
|
$ |
(5,838 |
) |
|
$ |
(11,540 |
) |
|
$ |
(11,039 |
) |
Purchase of property, plant,
and equipment |
|
|
(2,338 |
) |
|
|
(10,920 |
) |
|
|
(6,650 |
) |
|
|
(16,837 |
) |
Free Cash
Flow |
|
$ |
(6,194 |
) |
|
$ |
(16,758 |
) |
|
$ |
(18,190 |
) |
|
$ |
(27,876 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Investor Contacts
Matt Lowell
Chief Financial Officer
matt.lowell@teknova.com
+1 831-637-1100
Media Contact
Jennifer Henry
Senior Vice President, Marketing
jenn.henry@teknova.com
+1 831-313-1259
Sara Michelmore
MacDougall Advisors
smichelmore@macdougall.bio
+1 781-235-3060
Grafico Azioni Alpha Teknova (NASDAQ:TKNO)
Storico
Da Giu 2024 a Lug 2024
Grafico Azioni Alpha Teknova (NASDAQ:TKNO)
Storico
Da Lug 2023 a Lug 2024